Drug intelligence / Profile preview

JS0001

Development stage: Preclinical

Overview

**JS0001** is an unnamed preclinical aryl hydrocarbon receptor-modulating combination regimen evaluated in a syngeneic MOC1 mouse model of head and neck squamous cell carcinoma. The reported regimen reduced tumor-growth rate and improved progression-free survival versus anti-PD-1 control treatment, accompanied by reductions in systemic and intratumoral microbial tryptophan-pathway metabolites including indole-3-pyruvic acid. Its individual active components, formulation, route, manufacturer, and precise direction of aryl hydrocarbon receptor modulation have not been publicly disclosed. ([ascopubs.org](https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2026.44.16_suppl.e14594))

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on JS0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS0001.

Explore the full profile